Clinical trials: Invasive Breast Lobular Carcinoma
Breast Carcinoma, Breast Ductal Carcinoma In Situ
Effect of PACK Health Support Program on Patient Reported Outcomes in Patients With Breast Cancer
This trial studies the effect of an electronic health (eHealth) support program called PACK Health on patient reported health outcomes in patients with breast cancer.
- Conditions
- Breast Carcinoma, Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Recurrent Breast Carcinoma
- Trial name
- NCT04022772
- Testing
- Best Practice, Medical Chart Review, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 287 people
- Sponsor
- M.D. Anderson Cancer Center
Invasive Breast Cancer, Ductal Carcinoma in Situ of the Breast
Axillary Reverse Mapping (ARM) Technique
The purpose of this pilot study is to compare a new surgical technique (axillary reverse mapping) to standard axillary surgery in patients diagnosed with invasive or in situ breast cancer.
- Trial name
- ARM (NCT03109522)
- Testing
- axillary reverse mapping (ARM), Standard axillary surgery (SLNB or ALND)
- Where
- 2 sites in Canada
- Volunteers
- 130 people
- Sponsor
- McMaster University
Carcinoma, Ductal, Breast
Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer
The Neo-PREDICT-HER2 Study is phase II trial to validate predictive markers for the response evaluation of a combined chemo-immunotherapy in patients with HER2-positive early breast cancer.
- Trial name
- NCT01891357
- Testing
- Biopsy before and after three weeks of study treatment, paclitaxel, lapatinib
- Where
- 10 sites in Germany
- Volunteers
- 64 people
- Sponsor
- Women's Cancer Study Group GmbH
Metastatic Endocrine Refractory, Triple Negative Invasive Lobular Carcinoma
A Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma
To learn if ivonescimab can help to control endocrine-refractory HR+ HER2- and/or TN mILC.
- Trial name
- NCT07229417
- Testing
- Ivonescimab
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- M.D. Anderson Cancer Center
Invasive Ductal Breast Cancer, Carcinoma Breast Stage I
Lumpectomy Followed By Intraoperative Electron Radiation Therapy (IOERT)
The overall objective of this study is to determine the feasibility and tolerability of single dose Intraoperative Electron Radiation Treatment ("IOERT") as definitive therapy when administered at the time of breast conserving…
- Trial name
- NCT01960803
- Testing
- Intraoperative Electron Radiotherapy
- Where
- United States
- Sponsor
- Wake Forest University Health Sciences
Invasive Lobular Breast Carcinoma
Disease Extent in Stage IV Lobular Carcinoma: the Aid of Imaging and Liquid Biopsy Analyses
Metastatic invasive lobular carcinoma (ILC) is a distinct breast cancer subtype characterized by loss of E-cadherin and a diffuse growth pattern that makes metastases difficult to detect with standard imaging such as computed…
- Trial name
- DELILA (NCT07635654)
- Testing
- whole body diffusion weighted MRI, ctDNA
- Volunteers
- 43 people
- Sponsor
- KU Leuven
Estrogen Receptor-positive Breast Cancer, Invasive Ductal Breast Carcinoma
Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients With Hormone Responsive Stage 0-I Breast Cancer
This pilot clinical trial studies intensity-modulated accelerated partial breast irradiation (APBI) before surgery in treating older patients with estrogen receptor positive or progesterone receptor positive stage I breast…
- Conditions
- Estrogen Receptor-positive Breast Cancer, Invasive Ductal Breast Carcinoma, Invasive Ductal Breast Carcinoma With Predominant Intraductal Component, Medullary Ductal Breast Carcinoma With Lymphocytic Infiltrate
- Trial name
- NCT02186470
- Testing
- accelerated partial breast irradiation, intensity-modulated radiation therapy, image-guided radiation therapy
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Ductal Breast Carcinoma in Situ, Invasive Breast Cancer
Hypofractionated Radiation Therapy vs Standard Treatment in Breast Cancer.
An explanatory study comparing complementary treatment to breast conservative surgery with radiation therapy DCIS, T1-T2 N0 M0 (AJCC v8) 1 week schedule vs 3.1 weeks standard schedule, in order to determine the equivalence of…
- Conditions
- Ductal Breast Carcinoma in Situ, Invasive Breast Cancer, Early-stage Breast Cancer, Stage 0 Breast Cancer
- Trial name
- NCT05318274
- Testing
- Hypofractionated radiotherapy
- Where
- Mexico
- Volunteers
- 72 people
- Sponsor
- Coordinación de Investigación en Salud, Mexico
Invasive Ductal Carcinoma, Invasive Lobular Carcinoma
Intraoperative Imaging of Breast Cancer With Indocyanine Green
According to the World Health Organization, breast cancer is the most common cancer in women, and is responsible for 686,000 new cases every year. The WHO also posit that nearly 420,000 women perished from the disease in 2002.
- Conditions
- Invasive Ductal Carcinoma, Invasive Lobular Carcinoma, Ductal Carcinoma
- Trial name
- ICG (NCT01796041)
- Testing
- Indocyanine Green
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Breast Cancer
Radiation Therapy in Treating Women With Invasive Breast Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy in different ways may kill more tumor cells.
- Trial name
- NCT00301041
- Testing
- laboratory biomarker analysis, adjuvant therapy, radiation therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Francisco
Breast Cancer
3-Dimensional Conformal Radiation Therapy or Internal Radiation Therapy After Breast-Conserving Surgery in Treating Women With Stage I or Stage II Breast Cancer
RATIONALE: Specialized radiation therapy, such as 3-dimensional conformal radiation therapy, that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Trial name
- NCT00802711
- Testing
- 3-dimensional conformal radiation therapy, brachytherapy
- Where
- Ireland
- Volunteers
- 6 people
- Sponsor
- Cancer Trials Ireland
Tubular Breast Cancer, Mucinous Breast Cancer
Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients
The investigators hypothesize that paclitaxel combined with cisplatin in a weekly-based regimen as neoadjuvant chemotherapy is effective and tolerable for locally advanced breast cancer.
- Conditions
- Tubular Breast Cancer, Mucinous Breast Cancer, Invasive Ductal Breast Cancer, Inflammatory Breast Cancer
- Trial name
- SHPD002 (NCT02221999)
- Testing
- Paclitaxel, Cisplatin, Gonadotropin-releasing hormone agonist
- Where
- 12 sites in China
- Volunteers
- 250 people
- Sponsor
- RenJi Hospital
Breast Cancer
Radiation Therapy in Women With Low Risk Early-Stage Breast Cancer Who Have Undergone Breast Conservation Surgery
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy after surgery may kill any tumor cells that remain after surgery.
- Trial name
- IMPORT (NCT00814567)
- Testing
- radiation therapy
- Where
- United Kingdom
- Volunteers
- 2,018 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Breast Cancer
Simvastatin and Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ or Invasive Breast Cancer
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of simvastatin and anastrozole may stop cancer from forming, growing, or coming back in patients with invasive…
- Trial name
- NCT00354640
- Testing
- anastrozole, simvastatin, pharmacological study
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Cancer
Paclitaxel and Carboplatin in Treating Women Who Are Undergoing Surgery for Newly Diagnosed, Locally Advanced Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00096343
- Testing
- carboplatin, paclitaxel
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Alabama at Birmingham
Invasive Ductal Carcinoma, Ductal Carcinoma in Situ
Safety and Efficacy Study of the Xoft® Axxent® eBx® IORT System®
The purpose of this trial is to assess the safety and efficacy of the Xoft Axxent eBx System when used for single-fraction IORT in early stage breast cancer.
- Trial name
- NCT01644669
- Testing
- Intra-operative Radiation Therapy - IORT
- Where
- 24 sites in United States, Australia and 1 more
- Volunteers
- 1,200 people
- Sponsor
- Xoft, Inc.
Breast Cancer
Study of Blood Samples From High-Risk Postmenopausal Women Who Received Treatment on Breast Cancer Prevention Clinical Trials NSABP-P-1 or NSABP-P-2
RATIONALE: Studying the genes expressed in samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00967239
- Testing
- DNA analysis, polymorphism analysis, laboratory biomarker analysis
- Volunteers
- 1,881 people, healthy volunteers welcome
- Sponsor
- NSABP Foundation Inc
Artificial Intelligence (AI) in Diagnosis
Human-AI Collaborative INSIGHT Diagnostic Workflow for in Breast Cancer With Extensive Intraductal Component
The goal of this clinical trial is to see if an artificial intelligence (AI)-assisted method helps doctors more accurately detect invasive breast cancer in people with a specific type of tumor called "extensive intraductal…
- Trial name
- INSIGHT-EIC (NCT07060599)
- Testing
- INvasion Screening with Intelligent Guidance for Histopathology Triage (INSIGHT) Workflow
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Sun Yat-sen University
Breast Cancer
Doxorubicin Hydrochloride Liposome as First-Line Therapy in Treating Older Women With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00960336
- Testing
- pegylated liposomal doxorubicin hydrochloride
- Where
- France
- Volunteers
- 59 people
- Sponsor
- ARCAGY/ GINECO GROUP
Breast Cancer
Fast Spectral Imaging Device for Tumor Margin Mapping
The objective of the proposed research is to develop a clinical-trial-ready device and to evaluate its practical utility as a routinely used intra-operative tool.
- Trial name
- NCT01107080
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Duke University